• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Friday 09/21/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

WorldVentures

  • 5:51 PM

    OXFORD, Connecticut, January 8, 2016, NXTD, /PRNewswire/ — Nxt-ID, Inc. (NASDAQ: NXTD), a company focused on the growing m-commerce market and WorldVentures®, a privately held leading direct seller of vacation and entertainment club memberships and an Inc. 5000 fastest-growing company announced that on December 31, 2015, that WorldVentures completed a strategic investment of $2 million in Nxt-ID to develop a proprietary new wireless smart card for its members based on Nxt-ID’s Wocket®, a unique smart wallet that serves to securely

    Read more
  • 3:13 PM

    SILVER SPRING, Md., Jan. 04, 2016, PMCB, (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the Company’s 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia. PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are excited to see 2016 arrive as

    Read more
  • 3:50 PM

    ORLANDO, FL, IMUN, / ACCESSWIRE/ Immune Therapeutics Inc. a specialty biopharmaceutical company (OTCQB: IMUN) today provided an update on the ongoing clinical trial of Lodonal in Nigeria. The trial is an open-label, placebo-controlled study that includes a 90-day treatment period followed by a 60-day extension. The primary objective of this clinical trial is to confirm that Lodonal has a beneficial effect on the immune system of patients in Nigeria with a compromised immune system (refer to Inclusion/Exclusion Criteria). This will

    Read more
  • 3:17 PM

    SILVER SPRING, Md., Oct. 19, 2015, PMCB, OTCQB, (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its upcoming clinical trial designed to determine whether its pancreatic cancer treatment (Cell-in-a-Box® capsules + low-doses ifosfamide chemotherapy) can satisfy a critical unmet medical need for patients with pancreatic cancer will be conducted in the United States with additional study sites

    Read more
  • Accuray Logo
    2:00 PM

    Innovative System Provides Extremely Precise, Non-invasive Treatment in Four to Five Sessions SUNNYVALE, Calif., Oct. 13, 2015, ARAY, NASDAQ, /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) announced today that Anova Cancer Care in Denver, Colorado, has treated its 1,000th prostate cancer patient with the leading-edge CyberKnife® System. This non-invasive treatment for cancerous and non-cancerous tumors was designed to provide stereotactic body radiation therapy (SBRT), a treatment process enabling the delivery of radiation throughout the body with an extremely high degree of precision.

    Read more
  • 2:27 PM

    Sep 25, 2015 OTC Disclosure & News Service – FLEMINGTON, N.J., Sept. 25, 2015, OTCQB, ARNI, (GLOBE NEWSWIRE) — Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that a late-breaking abstract on AR-12 has been accepted for poster presentation at the upcoming 15th European AIDS Conference, hosted by the European AIDS Clinical Society (EACS) and being held October 21-24 in Barcelona, Spain. Logistical details

    Read more
Public Wire Banner